Study Finds Ivermectin ‘Did Not Prevent’ Severe COVID-19, but Doctors Alliance Calls It ‘Misleading’

Click here to read the full article.

A peer-reviewed study in which researchers concluded that ivermectin treatment during early COVID-19 “did not prevent” severe disease in high-risk patients has been criticized by an alliance of doctors for being “misleading.”

In the open-label randomized clinical trial, also referred to as the “The I-TECH Randomized Clinical Trial,” published in the JAMA Internal Medicine journal on Feb. 18, researchers said their findings “do not support the use of ivermectin for patients with COVID-19.”

The study involved results from 490 patients with mild to moderate COVID-19 in Malaysia. Participants were aged 50 and over, with at least one documented comorbidity. People who did not develop symptoms or who had severe COVID-19 were not included in the trial.

The trial was conducted in 20 hospitals and a COVID-19 quarantine center in the country between May 31 and Oct. 25, 2021. Of the group, 249 participants received standard care, while 241 received a course of oral ivermectin over five days in addition to standard care.

Continue reading here.

Scroll down for comments and share your thoughts!

What do you think?

Leave a Reply

Your email address will not be published.

GIPHY App Key not set. Please check settings

French Modeling Executive Accused of Helping Epstein Procure Young Girls Found Dead in Prison

US Agencies Quietly Studying Reports of Post-Vaccination Neurological Issues